Circulating circTOLLIP serves as a diagnostic biomarker for liquid biopsy in non-small cell lung cancer

Peng, Ziyi; Hu, Qiuzhi; Fang, Shuai; Zhang, Xun; Hong, Xin; Tao, Lili; Pan, Jinchang; Jiang, Meina; Bai, Huihui; Wu, Yinuo; Zhao, Xiaodong; Zhou, Chengwei; Chen, Jun; Han, Ying; Gong, Zhaohui

doi:10.1016/j.cca.2021.10.038

Cited by 9 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through further comprehensive studies, most of circRNAs remain stable in body fluids, including plasma, serum, exosomes, and urine 20 . Consistently, our previous study indicated that the expression of circTOLLIP was fairly stable in whole blood even if the storage condition changed 21 . In this work, we did not find a change of the relative expression of circUSP10 in whole blood from patients with NSCLC under different adverse conditions.…”

Section: Discussionsupporting

confidence: 88%

Whole Blood-Derived circUSP10 Acts as a Diagnostic Biomarker in Patients With Early-Stage Non-Small-Cell Lung Cancer

Bai,

Jiang,

Fang

et al. 2023

Cell Transplant

Self Cite

View full text Add to dashboard Cite

Accumulating evidence has indicated that differentially expressed noncoding circular RNAs (circRNAs) play essential roles in the occurrence and development of various types of cancer. Here, we aimed to identify and explore the diagnostic value of hsa_circ_0003026 (named circUSP10) in patients with early non-small-cell lung cancer (NSCLC). The differentially expressed circRNAs were screened from the microarray-based assay of human NSCLC tissues and their corresponding noncancerous tissues, and the candidate circRNAs were further verified in patients with NSCLC using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Circulating circUSP10 was isolated from whole blood of healthy people and patients with NSCLC and was detected by RT-qPCR. In addition, the diagnostic value of circUSP10 in early NSCLC was evaluated by receiver operating characteristic (ROC) curve analysis. We found that circUSP10 was upregulated in tumor tissues from patients with early NSCLC and associated with tumor size and tumor-node-metastasis (TNM) stage. Importantly, circUSP10 was obviously upregulated in the whole blood of patients with NSCLC. Additionally, whole blood–derived circUSP10 showed good diagnostic performance for screening early NSCLC and was relatively stable in blood under adverse conditions. These findings demonstrate that circUSP10 may act as a novel biomarker for the diagnosis of early-stage NSCLC, suggesting the potential of circUSP10 in RNA-based therapy for cancer.

show abstract

Section: Discussionsupporting

confidence: 88%

Whole Blood-Derived circUSP10 Acts as a Diagnostic Biomarker in Patients With Early-Stage Non-Small-Cell Lung Cancer

Bai,

Jiang,

Fang

et al. 2023

Cell Transplant

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, circRNAs have been detected in different peripheral blood components that include blood cells, extracellular vesicles as well as the plasma 152 . These components can be efficiently used as liquid biopsy markers for diagnosing different types of human diseases including cancer 153 , 154 . Likewise, the circRNAs interplaying with Hippo-YAP signaling may represent plausible diagnostic and prognostic biomarkers.…”

Section: Applications Of Hippo-yap Associated Circrnas In Cancer Ther...mentioning

confidence: 99%

Circular RNAs modulate Hippo-YAP signaling: functional mechanisms in cancer

Qadir¹,

Li²,

Yang³

2022

Theranostics

View full text Add to dashboard Cite

The Hippo signaling pathway is an evolutionarily conserved network that regulates organ size and tissue homeostasis in mammals. This pathway controls various cell functions, such as growth, proliferation, survival, apoptosis, and stemness by switching 'on' or 'off' its inhibitory and/or transcriptional module, thereby regulating target gene(s) expression. Altered Hippo signaling has been implicated in various forms of cancers. Increasing evidence suggests cross-talk between the Hippo signaling pathway and non-coding RNAs, in particular circular RNAs (circRNAs). In this context, the current review presents the mechanistic interplay between the Hippo pathway and related circRNAs in various forms of cancers, along with the capabilities of these circRNAs to function either as tumor suppressors or oncogenes through miRNA sponging or protein binding mechanisms. Furthermore, we discuss the constraints and limitations in circRNA mechanistic studies while highlighting some outstanding questions regarding the roles of circRNAs associated with the Hippo-YAP pathway in cancer. Finally, we delineate the potential of these circRNAs to be employed as diagnostic and prognostic biomarkers, as well as molecular hotspots for cancer therapy.

show abstract

“…According to our previous work [17], in brief, lung cancer cells were treated with actinomycin D (APExBIO, Houston, TX, USA) and then the expression levels of circRNA, as well as mRNA, were detected using reverse-transcription qPCR (RT-qPCR).…”

Section: Actinomycin D Assaymentioning

confidence: 99%

Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

Liang¹,

Zhang²,

Zhang³

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: Circular RNAs (circRNAs) are dysregulated in cancers and are stably expressed in body fluids such as blood. We therefore identified and evaluated the clinical value of a newly found circRNA VPS35L (circVPS35L) as a biomarker for the diagnosis of non-small cell lung cancer (NSCLC). Methods: Reverse-transcription quantitative PCR (RT-qPCR) was used to determine the expression levels of circVPS35L in tissues, whole blood, and cell lines. The actinomycin D assay and RNase R treatment were utilized to determine the stability of circVPS35L. Receiver operating characteristic (ROC) curve analysis was conducted to predict the diagnostic value of blood-derived circVPS35L in NSCLC. Results: CircVPS35L was found to be downregulated in NSCLC tissues and cell lines. Interestingly, circVPS35L expression was significantly correlated with tumor size (p = 0.0269), histology type (p < 0.0001), and TNM stage (p = 0.0437). Importantly, circVPS35L was poorly expressed in peripheral blood of NSCLC patients when compared with healthy controls and patients with benign lung disease. ROC analysis revealed a higher diagnostic value of circVPS35L than the three conventional tumor markers (CYFR21-1, NSE, and CEA) in patients with NSCLC. Moreover, circVPS35L was highly stable in peripheral blood when exposed to undesirable conditions. Conclusion: These findings demonstrate that circVPS35L has great potential as a novel biomarker for the diagnosis of NSCLC and can be used to distinguish NSCLC from benign lung disease.

show abstract

Circulating circTOLLIP serves as a diagnostic biomarker for liquid biopsy in non-small cell lung cancer

Cited by 9 publications

References 44 publications

Whole Blood-Derived circUSP10 Acts as a Diagnostic Biomarker in Patients With Early-Stage Non-Small-Cell Lung Cancer

Whole Blood-Derived circUSP10 Acts as a Diagnostic Biomarker in Patients With Early-Stage Non-Small-Cell Lung Cancer

Circular RNAs modulate Hippo-YAP signaling: functional mechanisms in cancer

Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About